January 7, 2016 GeneStrat blood-based mutation testing for advanced lung cancer offers significant advantages for patients and their treating physicians over standard tissue testing, which can delay treatment and increase patient risk due to complications from an invasive biopsy.
November 6, 2015
BOSTON– AACR-NCI-EORTC – November 6, 2015—Biodesix, Inc., today announced that its data on genomic and proteomic blood-based diagnostic assays will be presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. These blood-based diagnostic tests for patients with non-small cell lung cancer (NSCLC) are developed with a focus on results ... Read more
November 3, 2015
Biodesix, Inc. today announced new clinical findings showing that its novel investigational test, BDX008, based on profiling serum proteins, identifies patients with advanced melanoma who are more likely to have longer progression-free and overall survival with nivolumab therapy. Early data suggesting the test’s clinical potential for guiding anti-PD-1 therapy is being presented at the 30th ... Read more
September 7, 2015
Biodesix, Inc. today announced new data regarding VeriStrat®, a serum proteomic test, and epidermal growth factor receptor mutation status in a Phase 1B/2 study of cabozantinib +/- erlotinib in advanced non-small cell lung cancer that is being presented at the World Conference on Lung Cancer.
Details of the presentation are as follows:
MINI 08 – Prognostic/Predictive Biomarkers (ID106)
Moderators: ... Read more
August 13, 2015
Biodesix, Inc., a molecular diagnostics company that discovers and commercializes blood-based diagnostic tests to improve outcomes for patients with cancer, today announced that the company was named the 216th fastest-growing private company in America in the 2015 Inc.500|5000 list.
The Inc. 500, published annually by Inc. magazine, ranks privately-held businesses in the United States by percentage revenue growth over a three-year ... Read more
July 29, 2015
Biodesix, Inc., a molecular diagnostics company that discovers and commercializes blood-based diagnostic tests to improve outcomes for patients with cancer, and Biognosys AG, a leader in next-gen proteomics, today announced that Biodesix® will begin offering Biognosys’ HRM technology as part of its companion diagnostic development capabilities to develop novel protein assays for the oncology market.
As ... Read more
July 13, 2015
VeriStrat blood-based proteomic test continues to gain coverage across United States for patients with non-small cell lung cancer (NSCLC)
Biodesix, Inc. announced today that Health Net, Inc. (NYSE: HNT) is the latest insurer to announce a positive coverage decision for the VeriStrat® test. Health Net published its coverage policy for the VeriStrat proteomic serum test on ... Read more
June 23, 2015
Biodesix Inc., a molecular diagnostics company that researches, develops and commercializes rapid, blood-based tests for precision medicine in oncology, announced today that the company increased the size of its offering of series E preferred shares in a follow-on sale. In addition to the $27 million of series E shares sold from 2013 through 2015, the ... Read more
June 8, 2015
Blood-based proteomic test for patients with non-small cell lung cancer (NSCLC) now covered by three major national payers for a total of over 160 million covered lives
Biodesix, Inc. today announced that its VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation (NYSE: AET). Aetna published a positive coverage policy for the VeriStrat proteomic ... Read more
June 1, 2015
Blood-based proteomic test now covered for more than 115 Million lives in US
Biodesix, Inc. today announced that its VeriStrat® test received a positive coverage decision from Cigna Corporation (NYSE: CI). Cigna published its position to extend coverage for the VeriStrat blood-based test in May, stating the test is “…medically necessary for an individual with advanced non-small ... Read more